hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06376240 id: NL85203.068.23 briefTitle: The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes acronym: PYRAMID overallStatus: RECRUITING date: 2024-03-21 date: 2025-12-31 date: 2025-12-31 date: 2024-04-19 date: 2024-04-19 name: Maastricht University Medical Center class: OTHER name: Diabetes Fonds briefSummary: Patients with type 2 diabetes have an increased risk of developing vascular complications. Microvascular dysfunction might be caused by the increased production of methylglyoxal under hyperglycaemic conditions. Methylglyoxal is a by-product of glycolysis and forms advanced glycation endproducts (AGEs) on proteins and DNA, thereby disrupting their function. Preventing methylglyoxal accumulation and AGEs formation may offer a therapeutic option for treating microvascular complications in diabetics. Pyridoxamine is a vitamin B6 vitamer that scavenges methylglyoxal and thereby inhibits the formation of AGEs. In this study, the researchers investigate whether pyridoxamine supplementation in type 2 diabetes improves microvascular function in the eye, kidney and skin, and reduces markers of endothelial dysfunction and glycation. conditions: Type 2 Diabetes conditions: Microvascular Function conditions: Retinopathy, Diabetic conditions: Nephropathy, Diabetic conditions: Neuropathy, Diabetic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Pyridoxamine 300mg per day name: Placebo 300mg placebo per day measure: Central retinal artery equivalent of the eye measure: eGFR measure: Microvascular function in skin measure: Markers of endothelial function and glycation in blood plasma. measure: Advanced glycation end products in skin measure: Advanced glycation end products in blood plasma and urine measure: Adipokines and inflammatory markers in blood plasma measure: Methylglyoxal, glyoxal and 3-deoxyglucose in blood plasma. measure: Markers of dicarbonyl stress and oxidative stress in urine measure: Glucose metabolism measure: Liver fat measure: Systolic and diastolic blood pressure measure: Microvascular function eye measure: Urinary albumin sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Academic Hospital Maastricht status: RECRUITING city: Maastricht zip: 6229 HX country: Netherlands name: CTCM Clinical Trial Center Maastricht role: CONTACT phone: + 31 (0) 43 387 20 40 email: secretariaat.ctcm@mumc.nl lat: 50.84833 lon: 5.68889 hasResults: False
nctId: NCT06376227 id: jamesdukeryan briefTitle: Robotic-Assisted or Laparoscopic Radical Resection for Rectal Cancer With or Without Left Colic Artery Preservation overallStatus: COMPLETED date: 2020-04-01 date: 2023-05-31 date: 2023-12-28 date: 2024-04-19 date: 2024-04-22 name: Northern Jiangsu People's Hospital class: OTHER briefSummary: Brief Summary
Background The preservation of the left colic artery (LCA) during rectal cancer resection remains a topic of controversy, and there is a notable absence of robust evidence regarding the outcomes associated with LCA preservation. And the advantages of robotic-assisted laparoscopy (RAL) surgery in rectal resection remain uncertain. The objective of this study was to assess the influence of LCA preservation surgery and RAL surgery on intraoperative and postoperative complications of rectal cancer resection.
Methods Participants who underwent laparoscopic (LSC) or RAL with or without LCA preservation resection for rectal cancer between April 2020 and May 2023 were retrospectively assessed. The patients were categorized into two groups: low ligation (LL) which with preservation of LCA and high ligation (HL) which without preservation of LCA. A one-to-one propensity score-matched analysis was performed to decrease confounding. The primary outcome was operative findings, operative morbidity, and postoperative genitourinary function. conditions: Rectal Cancer conditions: Left Colic Artery Stenosis (Diagnosis) conditions: Robotic Assisted Laparoscopic Surgery studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1164 type: ACTUAL name: with or without Left Colic Artery Preservation measure: The incidence of anastomotic leakage in postoperative patients with or without left colic artery preservation. measure: The genitourinary function of the patients after the radical resection with or without left colic artery preservation. sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Northern Jiangsu People's Hospital Affiliated to Yangzhou University, General Surgery Institute of Yangzhou, Yangzhou University , Yangzhou city: Yangzhou state: Jiangsu zip: 225001 country: China lat: 32.39722 lon: 119.43583 hasResults: False
nctId: NCT06376214 id: 2024-02 briefTitle: Daratumumab for Patients With Light Chain Amyloidosis overallStatus: RECRUITING date: 2023-01-01 date: 2025-12-31 date: 2026-12-31 date: 2024-04-19 date: 2024-04-19 name: Nanjing University School of Medicine class: OTHER briefSummary: This is a prospective, single-center study exploratory clinical trial, aim to exploring the efficacy and safety of daratumumab in patients with AL amyloidosis, patients were divided into three groups: one group received long-term treatment with daratumumab based regimen, and the other group received autologous stem cell transplantation after two standard treatment courses with daratumumab based regimen, and the third group consists of newly diagnosed stage IIIb AL amyloidosis patients who plan to receive DPD treatment. The purpose of this study is to observe the efficacy and safety of Daratumumab, in the treatment of newly diagnosed systemic AL amyloidosis. conditions: Light Chain (AL) Amyloidosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Dratumumab / Hyaluronidase Injection [Darzalex Faspro] name: Pomalidomide 4 MG name: autologous stem cell transplantation (ASCT) measure: Hematological complete response rate measure: Organ response rate measure: Time to Next Treatment measure: Progression-free survival measure: Overall survival sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Clinical Research Center for Kidney Diseases, Jinling Hospital status: RECRUITING city: Nanjing state: Jiangsu zip: 210016 country: China name: Xianghua Huang, MD role: CONTACT phone: 02580862351 email: hxhszb@163.com lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06376201 id: NFEC-2024-018 briefTitle: A Clinical Study on the Efficacy and Safety of ABCD in the Treatment of Patients With Invasive Fungal Disease overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-02 date: 2025-09 date: 2024-04-19 date: 2024-04-19 name: Nanfang Hospital, Southern Medical University class: OTHER briefSummary: This study is a prospective, multicenter, single-arm study, that aims to evaluate the efficacy and safety of amphotericin B cholesterol-sulfate complex (ABCD) for injection in the first-line treatment of patients with invasive fungal diseases, hoping to provide a reference for the clinical treatment of invasive fungal diseases. Patients with hematologic diseases who meet the criteria for inclusion and discharge with febrile neutropenia and suspected fungal infection were treated with ABCD antifungal therapy for 14 days while receiving treatment for underlying diseases, and the response rate of treatment was observed. conditions: Invasive Fungal Disease studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 125 type: ESTIMATED name: Amphotericin B cholesterol-sulfate complex for injection measure: Treatment is effective measure: Incidence of the single index in the five criteria of treatment success measure: Completion rate of ABCD treatment for at least 14 days sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06376188 id: 1582/2021 SimCom briefTitle: Improving Breaking Bad News in Pediatrics by Simulated Communication acronym: SimCom overallStatus: COMPLETED date: 2021-09-01 date: 2022-08-31 date: 2022-09-30 date: 2024-04-19 date: 2024-04-19 name: Medical University of Vienna class: OTHER briefSummary: Breaking bad news, especially a death notice, is an essential part of the medical profes-sional communication. Being inadequately trained in those skills this may result in un-pleasant psychosocial consequences for everyone involved.
This prospective, single-center, randomized controlled trial evaluated the delivery of a death notice to simulation parents out of the perspective of these parents (professional actors), the participants (students) and by video analysis. The simulation patient has prior unexpectedly died during a simulated resuscitation. The intervention group broke the bad news after receiving a short communication conditions: Communication conditions: End of Life conditions: Pediatric ALL studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 46 type: ACTUAL name: communication training measure: score by simulation parents measure: score by participants measure: score of video analysis sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medical University of Vienna city: Vienna zip: 1090 country: Austria lat: 48.20849 lon: 16.37208 hasResults: False
nctId: NCT06376175 id: LL-016 briefTitle: Task Atlas: Study to Develop a Task Atlas of Brain Recruitment During a Digital Game-based Program overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-08-31 date: 2024-08-31 date: 2024-04-19 date: 2024-04-19 name: Lumos Labs, Inc. class: INDUSTRY briefSummary: Healthy volunteers ages 25-40 from the general US population who meet the eligibility criteria and are enrolled will (a) play Lumosity games at least 20 times each in under 60 days and (b) then complete one session of task-based functional magnetic resonance imaging (fMRI) while playing Lumosity games. conditions: Healthy Adults studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 40 type: ESTIMATED measure: BOLD response during gameplay measure: Responder rates measure: Structural MRI volumetrics: Volume measure: Structural MRI volumetrics: Cortical thickness measure: Structural MRI volumetrics: Brain-Predicted Age Difference measure: Behavior response: Game score measure: BAMS-7 (Brief Attention and Mood Scale of 7 Items) measure: VGPQ (Video Game Playing Questionnaire) sex: ALL minimumAge: 25 Years maximumAge: 40 Years stdAges: ADULT facility: UC Davis Imaging Research Center (IRC) city: Sacramento state: California zip: 95817 country: United States name: Kevin Madore, PhD role: CONTACT lat: 38.58157 lon: -121.4944 hasResults: False
nctId: NCT06376162 id: ITCC-101/APAL2020K id: 2023-505262-28-00 type: CTIS briefTitle: Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2027-08 date: 2027-08 date: 2024-04-19 date: 2024-04-19 name: LLS PedAL Initiative, LLC class: OTHER name: Kura Oncology briefSummary: The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or NPM1-m acute leukemia based on safety and pharmacokinetics (PK). conditions: Relapsed/Refractory KMT2A-r Acute Leukemia conditions: Relapsed/Refractory NUP98-r Acute Leukemia conditions: Relapsed/Refractory NPM1-m Acute Leukemia studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Ziftomenib name: Cytarabine name: Fludarabine measure: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) measure: Area Under the Plasma Concentration-time Curve (AUC) of Ziftomenib measure: Number of Participants Who Experience an Adverse Event (AE) measure: Number of AEs by Severity measure: Maximum Observed Plasma Concentration (Cmax) of Ziftomenib measure: Minimum Observed Plasma Concentration (Cmin) of Ziftomenib measure: Time to Cmax (Tmax) measure: Truncated AUC (AUC0-t) of Ziftomenib in Combination with FLA Chemotherapy measure: Extrapolated AUC (AUC0-∞) of Ziftomenib in Combination with FLA Chemotherapy measure: Oral Plasma Clearance (CL/F) of Ziftomenib in Combination with FLA Chemotherapy measure: Volume of Distribution (Vz/F) of Ziftomenib in Combination with FLA Chemotherapy measure: Terminal Elimination Half-life (t1/2) of Ziftomenib in Combination with FLA Chemotherapy measure: HSCT Rate measure: Morphological Overall Response Rate (ORR) measure: Flow-based ORR measure: Flow-based Measurable Residual Disease (MRD) Negativity Rate measure: Duration of Response (DOR) measure: Event-free Survival (EFS) measure: Overall Survival (OS) measure: Cumulative Incidence of Relapse (CIR) sex: ALL minimumAge: 0 Years maximumAge: 21 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06376149 id: 124973 briefTitle: M3-JIA: Making Mindfulness Matter for Children With JIA acronym: M3-JIA overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2025-12 date: 2026-02 date: 2024-04-19 date: 2024-04-29 name: Lawson Health Research Institute class: OTHER name: Brain Canada briefSummary: The investigator will evaluate the efficacy of M3©, an intervention for patients with JIA and their caregivers. Children with Juvenile arthritis and their parents will attend an 8 week online program called Making Mindfulness Matter (M3). This is a facilitator-led program that integrates knowledge and skills related to mindfulness, social-emotional learning, neuroscience, and positive psychology to promote coping and resiliency for children and families in context of the challenges of pediatric chronic disease. The child program is designed for children 4-12 years of age, with each lesson including a variety of concrete ways to teach children skills based on their age/developmental level. conditions: Juvenile Idiopathic Arthritis conditions: Children conditions: Mental Health conditions: Mental Well-being studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The primary objective is to conduct a pilot RCT to evaluate the effectiveness of a live-online mindfulness-based family intervention program, Making Mindfulness Matter (M3©) for children with JIA and their caregiver(s).
Additionally, at the start of each session, parents will complete a one-page semi-structured questionnaire evaluating treatment fidelity and at home utilization of M3© skills. At the end of each session, parent participants will complete a one-page structured questionnaire providing feedback on the session, and facilitators will complete the M3© Adherence Checklist, evaluating whether planned activities were completed, and any modifications made. primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE maskingDescription: Participants will be blinded to their group assignment: all participants will be told that they will receive the intervention. Program facilitators will be blinded to participant group assignment order, since sessions for both study arms would run on a rolling basis. The statistician will also be blinded to the group assignment and order. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 74 type: ESTIMATED name: M3 Intervention group name: M3 Waitlist Group measure: conduct a pilot RCT to evaluate the effectiveness of a live-online mindfulness-based family intervention program, Making Mindfulness Matter (M3©) for children with JIA and their caregiver(s). measure: Effects of M3 on health related quality of life of children with JIA measure: Effects of M3 on health quality of life for parents measure: Does M3 have a positive effect on children's severity of JIA measure: Does M3 have a positive effect on children's executive function measure: Does M3 have a positive effect on parents' stress measure: Does M3 have a positive effect on parents' depression and anxiety measure: Does M3 have a positive effect on Child's' depression and anxiety measure: Does M3 have a positive effect on children's resiliency measure: Does M3 have a positive effect on parent resiliency sex: ALL minimumAge: 4 Years maximumAge: 12 Years stdAges: CHILD facility: McMaster Children's Hospital, city: Hamilton state: Ontario zip: L8N 3Z5 country: Canada name: Karen Beatie role: CONTACT phone: (905) 521-2100 email: beattik@mcmaster.ca name: Michelle Dr. Batthish role: CONTACT phone: (905) 521-2100 email: batthim@mcmaster.ca name: Michelle Batthish role: SUB_INVESTIGATOR lat: 43.25011 lon: -79.84963 facility: London Health Sciences Centre- Children's Hosptial city: London state: Ontario zip: N6J 4L8 country: Canada name: Sarah Wells role: CONTACT phone: 519-685-8500 phoneExt: 56816 email: sarah.wells@lhsc.on.ca name: Roberta Berard role: CONTACT phone: 519-685-8500 phoneExt: 52479 email: roberta.berard@lhsc.on.ca name: Roberta Berard, MD role: PRINCIPAL_INVESTIGATOR lat: 42.98339 lon: -81.23304 facility: Sickids city: Toronto state: Ontario zip: M5G 1E8 country: Canada name: Andrea Knight role: CONTACT phone: (416) 813-1500 email: andrea.knight@sickkids.ca name: Andrea Dr. Knight role: SUB_INVESTIGATOR lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06376136 id: BAT-8010+1006-001-CR briefTitle: An Evaluation of BAT 8010 for Injection in Combination With BAT 1006 in Locally Advanced or Metastatic Entities Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of the Tumor in Patients Multicenter, Open Phase Ib/IIa Clinical Study overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2024-05-24 date: 2026-12-09 date: 2024-04-19 date: 2024-04-19 name: Bio-Thera Solutions class: INDUSTRY briefSummary: This study is a multicenter, open, exploratory Phase Ib/IIa clinical trial in humans The combination of BAT8010 and BAT1006 was administered in patients with locally advanced or metastatic solid tumors(HER-2 expression, including IHC3+, IHC2+/FISH+, and IHC2+/FISH- patients)Tolerance and PK characteristics, to explore the maximum tolerated dose (MTD) and provide recommendations for subsequent clinical studies Recommended dose (RP2D) and rational administration regimen, and preliminary evaluation of antitumor efficacy. There are two main studies In the first stage, the "3+3" dose escalation rule is proposed to explore the safety and tolerance of the drug Sex; The second stage selects the appropriate dose and administration according to the preliminary safety and efficacy results of the previous stage The drug regimen and tumor species were expanded to further explore the combination of BAT8010 and BAT1006 for injection，The safety and clinical effectiveness of drug administration provided the basis for the follow-up clinical study. conditions: Advanced Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 108 type: ESTIMATED name: BAT8010 for Injection name: BAT1006 for Injection measure: Dose-limiting toxicity (DLT) measure: vital signs measure: Physical examination measure: Adverse events measure: Clinical laboratory tests measure: Number of participants with abnormal clinical auxiliary tests measure: Duration of Response(DOR) measure: Disease Control Rate (DCR) measure: Pharmacokinetic measure: Pharmacokinetic measure: Pharmacokinetic measure: Pharmacokinetic measure: Antibody measure: Antibody sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06376123 id: Nkangarli001 briefTitle: Nomogram for Prediction of Alveolo-arterial Gradient During One-lung Ventilation overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-09-01 date: 2024-09-15 date: 2024-04-19 date: 2024-04-19 name: Bezmialem Vakif University class: OTHER briefSummary: The cause of hypoxia during one-lung ventilation is a common anaesthetic problem seen during thoracic surgery and is associated with increased fraction of shunted blood. This shunt occurs because the lung not participating in respiration stops saturating the blood with oxygen. The importance of our study is to collect some of the patient's parameters on a nomogram in the preoperative period, to predict the shunt fraction that will occur during one-lung ventilation and to make preparations and interventions accordingly. conditions: One-lung Ventilation studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 40 type: ESTIMATED measure: Alveolo-arterial gradient measure: Alveolo-arterial gradient measure: Alveolo-arterial gradient change measure: Alveolo-arterial gradient change sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bezmialem Vakif University Dragos Hospital city: Istanbul state: Maltepe zip: 34844 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06376110 id: AviClear-001 briefTitle: Single-Blind Study Assessing the Use of a Topical Antioxidant With A Series of Laser Procedures to Reduce Sebum Production overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-04-15 date: 2025-04-15 date: 2024-04-19 date: 2024-04-19 name: Austin Institute for Clinical Research class: NETWORK name: SkinCeuticals briefSummary: This is a split-face, single-blind study assessing the use of an antioxidant serum with a series of acne laser treatments to reduce sebum production in healthy male and female subjects between the ages of 18 and 65 years, inclusive, with Fitzpatrick skin types I-VI. conditions: Acne studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 10 type: ESTIMATED name: Topical Antioxidant Serum name: AviClear Laser measure: Change in Product Tolerability measure: Change in Product Efficacy sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06376097 id: D5162R00036 briefTitle: Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service. overallStatus: RECRUITING date: 2023-04-19 date: 2025-01-30 date: 2025-01-30 date: 2024-04-19 date: 2024-04-19 name: AstraZeneca class: INDUSTRY briefSummary: Observational study that aims to evaluate the implementation of a lung cancer screening program in a smoker population included in a public heath service. conditions: Lung Cancer studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED measure: Absolute number and frequency of false-negative lung nodules . measure: Assess adherence to smoking cessation treatment in active smokers who enter screening. measure: Assessment of morbidity and mortality in patients undergoing invasive procedures, whether diagnostic or therapeutic. measure: Cost comparasion of treating patients in metastatic setting vs. treating early-stage lung cancer patients, including all costs from the screening program. sex: ALL minimumAge: 45 Years maximumAge: 74 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital das Clínicas da Faculdade de Medicina de Botucatu (HCFMB) status: RECRUITING city: Botucatu state: São Paulo zip: 18618-686 country: Brazil name: Erica Hasimoto role: CONTACT phone: (14) 99792-0222 email: ericanh80@hotmail.com lat: -22.88583 lon: -48.445 hasResults: False